Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Intra-articular metHuIL-1ra · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Anakinra | EXPERIMENTAL | anakinra |
| placebo | PLACEBO_COMPARATOR | placebo |
| Name | Type | Description |
|---|---|---|
| Intra-articular metHuIL-1ra (anakinra) | DRUG | anakinra |
| placebo | DRUG | placebo |
Inclusion Criteria: - Diagnosed with knee OA as determined by American College of Rheumatology (ACR) criteria - Pain defined by a level of greater than 30 mm on a 100 mm Visual Analogue Scale (VAS) - No evidence of active effusion or inflammatory flare, confirmed by investigator - Must exhibit radio...
Intra-articular metHuIL-1ra is an investigational small molecule being studied for the treatment of osteoarthritis. It is administered intra-articularly, meaning directly into the joint. The drug is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
Intra-articular metHuIL-1ra is being developed by Amgen Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol AMGN. The drug is in Phase 2 clinical development for osteoarthritis.
Intra-articular metHuIL-1ra is in Phase 2 clinical development. It is an investigational drug and has not been approved for any use. A Phase 2 clinical trial for the treatment of osteoarthritis of the knee has been completed.
Intra-articular metHuIL-1ra has been studied in one completed Phase 2 clinical trial, identified as NCT00110916. This trial enrolled 165 participants and evaluated the drug for the treatment of osteoarthritis of the knee. The trial was randomized, double-blind, and placebo-controlled.
Yes, Intra-articular metHuIL-1ra is classified as a small molecule therapeutic. It is being developed for the musculoskeletal therapeutic area, specifically for the treatment of osteoarthritis.